Abstract: Provided is the use of an insulin-like growth factor-2 for preparing a pharmaceutical composition, wherein the pharmaceutical composition is used for (i) promoting the expression of the macrophage PD-L1, and/or (ii) inhibiting the expression of the macrophage IL-?. Also provided is a pharmaceutical composition containing insulin-like growth factor-2 as an active ingredient.

Abstract: Provided is an application of a non-IGF1R-binding substance in the prevention and/or treatment of inflammatory diseases. Specifically, provided is use of a non-IGF1R-binding substance. The non-IGF1R-binding substance is used for preparing a composition or formulation, and the composition or formulation is used for preventing and/or treating inflammatory diseases.

Abstract: Disclosed are RNA site-directed editing using artificially constructed RNA editing enzymes and related uses. Provided is the fusion of an RNA recognition domain for binding RNA and a functional effector domain to form a new functional protein. The new functional protein specifically targets target RNA by means of the recognition domain and performs RNA editing using the effector domain.

Abstract: Provided are a circular RNA construct and application thereof. The circular RNA construct has a structure represented by formula I in the 5?-3? direction: TI-Z1-Z2 (I), wherein TI is a translation initiation element, Z1 is an expression cassette for exogenous protein expression, and Z2 is nothing or another element.

Abstract: Disclosed are a novel tumor microenvironment-related target TAK1 and an application thereof in inhibition of a tumor. TAK1, as a research target for SASP regulation, can be used as a marker in tumor diagnosis and prognosis, and can also be used as a tumor microenvironment specific target to develop tumor inhibitory drugs.

Abstract: An assisted early screening system for Down syndrome, relating to assisted screening of Down syndrome skin prints based on a machine learning algorithm, wherein the system comprising: (a) a skin print feature input module; (b) a processing module for diagnosis of Down syndrome based on skin print, wherein the processing module performs a scoring processing on the inputted skin print features according to a predetermined evaluation criteria to obtain a risk score, and compares the risk score with a Down syndrome risk threshold, thereby obtaining an assisted screening result; and (c) an output module for assisted screening result, which is configured to output the assisted screening result. The assisted early screening system for Down syndrome can implement simple, accurate, and effective assisted early screening of Down syndrome, such that powerful assistance can be provided for postnatal early intervention for early Down syndrome patients.

Abstract: Provided is an application of an ICAM-1 marker and a regulating agent thereof in promoting or inhibiting differentiation of adipose-derived stem cells into adipose cells, and an application of ICAM-1 or detection reagent thereof in (a) detecting adipose-derived stem cells, and/or (b) determining the risk of a subject suffering from obesity and a corresponding diagnostic kit and method. Further provided is an in vitro non-therapeutic preparation method for fat cells.